{"disease":{"id":"edema-in-cirrhotic-patients-unresponsive-to-fluid-and-sodium-restriction","name":"Edema in cirrhotic patients unresponsive to fluid and sodium restriction","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"aldactone","indication_name":"Edema in cirrhotic patients unresponsive to fluid and sodium restriction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"aldactone","guideline_body":"FDA label","recommendation":"Spironolactone is indicated for the management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions.","line_of_therapy":"2L","evidence_grade":"1B","guideline_year":null},{"drug_id":"aldactone","guideline_body":"FDA label","recommendation":"Spironolactone is indicated for the management of edema in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response.","line_of_therapy":"2L","evidence_grade":"1B","guideline_year":null}],"source":"Drug Landscape verified database"}